vs
Side-by-side financial comparison of Atara Biotherapeutics, Inc. (ATRA) and EMERSON RADIO CORP (MSN). Click either name above to swap in a different company.
EMERSON RADIO CORP is the larger business by last-quarter revenue ($1.9M vs $1.6M, roughly 1.2× Atara Biotherapeutics, Inc.). On growth, EMERSON RADIO CORP posted the faster year-over-year revenue change (-52.8% vs -95.1%). Over the past eight quarters, EMERSON RADIO CORP's revenue compounded faster (-7.3% CAGR vs -75.9%).
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
Emerson Radio Corporation is one of the United States' largest volume consumer electronics distributors and has a recognized trademark in continuous use since 1912. The company designs, markets, and licenses many product lines worldwide, including products sold, and sometimes licensed, under the brand name G Clef, an homage to Emerson's logo.
ATRA vs MSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $1.9M |
| Net Profit | — | $-694.0K |
| Gross Margin | — | 10.9% |
| Operating Margin | — | -43.7% |
| Net Margin | — | -36.7% |
| Revenue YoY | -95.1% | -52.8% |
| Net Profit YoY | 73.2% | -31.7% |
| EPS (diluted) | — | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $1.9M | ||
| Q3 25 | $3.5M | $1.2M | ||
| Q2 25 | $17.6M | $1.7M | ||
| Q1 25 | $98.1M | $1.8M | ||
| Q4 24 | $32.8M | $4.0M | ||
| Q3 24 | $40.2M | $2.7M | ||
| Q2 24 | $28.6M | $2.2M | ||
| Q1 24 | $27.4M | $2.2M |
| Q4 25 | — | $-694.0K | ||
| Q3 25 | $-4.3M | $-1.0M | ||
| Q2 25 | $2.4M | $-1.1M | ||
| Q1 25 | $38.0M | $-2.4M | ||
| Q4 24 | $-12.7M | $-527.0K | ||
| Q3 24 | $-21.9M | $-881.0K | ||
| Q2 24 | $-19.0M | $-962.0K | ||
| Q1 24 | $-31.8M | $-883.0K |
| Q4 25 | — | 10.9% | ||
| Q3 25 | — | -0.1% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | -3.0% | ||
| Q4 24 | — | 12.3% | ||
| Q3 24 | — | 9.9% | ||
| Q2 24 | — | 8.8% | ||
| Q1 24 | — | 15.9% |
| Q4 25 | — | -43.7% | ||
| Q3 25 | -103.5% | -98.4% | ||
| Q2 25 | 18.2% | -78.1% | ||
| Q1 25 | 39.5% | -137.8% | ||
| Q4 24 | -37.3% | -18.3% | ||
| Q3 24 | -54.1% | -40.8% | ||
| Q2 24 | -63.7% | -55.6% | ||
| Q1 24 | -114.2% | -52.2% |
| Q4 25 | — | -36.7% | ||
| Q3 25 | -124.6% | -85.8% | ||
| Q2 25 | 13.6% | -68.1% | ||
| Q1 25 | 38.7% | -127.9% | ||
| Q4 24 | -38.8% | -13.2% | ||
| Q3 24 | -54.5% | -32.2% | ||
| Q2 24 | -66.5% | -43.8% | ||
| Q1 24 | -116.1% | -40.1% |
| Q4 25 | — | $-0.03 | ||
| Q3 25 | $-0.32 | $-0.05 | ||
| Q2 25 | $0.19 | $-0.05 | ||
| Q1 25 | $3.50 | $-0.10 | ||
| Q4 24 | $0.27 | $-0.03 | ||
| Q3 24 | $-2.93 | $-0.04 | ||
| Q2 24 | $-3.10 | $-0.05 | ||
| Q1 24 | $-5.65 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $13.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.5M | $18.6M |
| Total Assets | $20.2M | $20.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $13.3M | ||
| Q3 25 | $13.7M | $13.5M | ||
| Q2 25 | $22.3M | $15.5M | ||
| Q1 25 | $13.8M | $16.1M | ||
| Q4 24 | $42.5M | $16.4M | ||
| Q3 24 | $67.2M | $16.7M | ||
| Q2 24 | $35.3M | $18.9M | ||
| Q1 24 | $46.2M | $19.9M |
| Q4 25 | $-38.5M | $18.6M | ||
| Q3 25 | $-36.6M | $19.3M | ||
| Q2 25 | $-35.0M | $20.4M | ||
| Q1 25 | $-55.1M | $21.5M | ||
| Q4 24 | $-97.3M | $23.9M | ||
| Q3 24 | $-90.5M | $24.4M | ||
| Q2 24 | $-110.9M | $25.3M | ||
| Q1 24 | $-98.3M | $26.2M |
| Q4 25 | $20.2M | $20.1M | ||
| Q3 25 | $30.2M | $20.7M | ||
| Q2 25 | $36.9M | $23.3M | ||
| Q1 25 | $62.0M | $23.5M | ||
| Q4 24 | $109.1M | $26.4M | ||
| Q3 24 | $142.7M | $26.6M | ||
| Q2 24 | $117.3M | $28.5M | ||
| Q1 24 | $165.3M | $29.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.9M | $-228.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-50.9M | $-228.0K | ||
| Q3 25 | $-9.8M | $-2.0M | ||
| Q2 25 | $-7.3M | $-514.0K | ||
| Q1 25 | $-28.1M | $-391.0K | ||
| Q4 24 | $-24.5M | $-293.0K | ||
| Q3 24 | $-4.0M | $-2.1M | ||
| Q2 24 | $-10.6M | $-840.0K | ||
| Q1 24 | $-29.6M | $-2.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-24.6M | $-301.0K | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | $-10.7M | $-1.0M | ||
| Q1 24 | $-29.7M | $-2.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -75.0% | -7.5% | ||
| Q3 24 | — | -77.8% | ||
| Q2 24 | -37.3% | -46.4% | ||
| Q1 24 | -108.7% | -102.3% |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.3% | 0.2% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.1% | 8.2% | ||
| Q1 24 | 0.5% | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | -0.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRA
Segment breakdown not available.
MSN
| Products | $1.8M | 95% |
| Other | $87.0K | 5% |
